Conference Menu

Overview
Register
PDF Download
Short Course
Posters
Hotel & Travel 
Sponsorship & Exhibits
Attendee Profile 2013
Press Pass 
Request Brochure 
Archives 

Co-Located Event: The Immunotherapies & Vaccines Summit 

Corporate Sponsors 

 

Novozymes (white) 

Peregrine 

WorldCare Clinical LLC 

Media Partners 

Bentham Science Logo 

Bio-IT-Word_logo 

Biospace 

eCliniqua 

GEN-New Logo 

GenomeWeb 

Nature_logo 

Pharmaphorum 

PharmaVoice 

Science AAAS 

The Scientist 


The Immunotherapies Congress


2013 Archived Content

 

Recent advances in cancer immunotherapy have turned researcher's attentions to new therapeutic strategies focused on improved specificity, control of key checkpoints in immune response, the identification of new biomarkers and novel ways of combining therapies for maximum effect. The two-conference Immunotherapies Congress offers an exciting opportunity to learn how these strategies are being translated into the next generation of cancer immunotherapeutic drug products.

The first meeting, Emerging Cancer Immunotherapies and Vaccines, will examine new targets and strategies in this space, and explore how the lessons learned from early cancer vaccines are driving development of longer-lasting and more potent immune responses. A second conference, Immunomodulatory Therapeutic Antibodies for Cancer showcases the exciting wave of checkpoint blockades such as anti-PD-1 and antii-CTLA-4 now in clinical development – and explores considerations of trial design, drug safety and biomarker discovery that will influence their application in patients.


Sessions Include: 

  • Cancer Biology and Biomarkers
  • Emerging Cancer Immunotherapies & Vaccines
  • Clinical Development of Immunomodulatory Antibodies
  • Bispecific Immunomodulatory Antibodies

Keynote Presentation: 

The Promise of T-Cell Engineering 

Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center 

Immune Monitoring on Pre-surgical Clinical Trials with a Novel Checkpoint Blockade Agent, Anti-CTLA-4 

Padmanee Sharma, M.D., Associate Professor, Genitourinary Medical Oncology,University of Texas MD Anderson Cancer Center 

Pre-Conference Short Course: 

Melanoma Biology and Immunotherapies 

Manufacturing Vaccines: New Approaches, New Technologies 



By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs